Quantcast

Latest Mantle cell lymphoma Stories

2014-04-21 12:27:29

SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE(TM)) study of single agent IMBRUVICA(TM) (ibrutinib) vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of IMBRUVICA after three years of follow-up, will be presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago, Illinois May 30 - June...

2014-04-08 08:31:42

New submission based on positive Phase 3 data from the RESONATE(TM) trial RARITAN, N.J., April 8, 2014 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA(TM) (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. This regulatory submission is based on data from the Phase 3 RESONATE(TM) study in relapsed or refractory chronic...

2014-04-08 08:31:34

SUNNYVALE, Calif., April 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATE(TM) study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICA(TM) (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who...

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North Carolina (PRWEB) March 25, 2014 Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at...

2014-03-22 23:02:28

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC (PRWEB) March 22, 2014 Scientists studying the Non-Hodgkin’s Lymphoma drug Zolinza (vorinostat) say it may improve outcomes for patients fighting indolent B-cell lymphomas like follicular lymphoma and mantle cell lymphoma. The Phase II study, published in the British Journal of Haematology and reported by the Non-Hodgkin’s...

2014-03-12 23:24:38

Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh, NC (PRWEB) March 12, 2014 According to the Non-Hodgkin’s Lymphoma Center, a study published in the journal Blood suggests that patients with certain kinds of Non-Hodgkin’s Lymphomas may get equally good results from a new chemotherapy combination than from the standard drugs. Researchers at the Sarah Cannon Research Institute...

2014-03-11 08:32:04

NEWTOWN, Pa., March 11, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of specialized outsourced clinical trial services, today announced that its technology was utilized by Pharmacyclics, Inc. (NASDAQ: PCYC) and supported the accelerated approval of IMBRUVICA(TM) (ibrutinib) for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). http://photos.prnewswire.com/prnvar/20130403/PH87647LOGO The Phase III clinical program supporting IMBRUVICA's early approval...

2014-03-10 12:24:08

WASHINGTON, March 10, 2014 /PRNewswire-USNewswire/ -- A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports* published online today in Blood, the journal of the American Society of Hematology. Patients with blood cancer are typically administered a combination of chemotherapy and immunotherapy, the latter using...

2014-02-22 23:01:25

Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a newly-published article illustrating the potential dangers of rituximab therapy. Rituximab is a monoclonal antibody that is often used along with traditional chemotherapy in the treatment of Non-Hodgkin’s Lymphoma and other cancers involving the immune system B-cells....

2014-02-20 16:25:31

Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013. Financial Results for the Quarter and Year Ended December 31, 2013 Revenue Total revenue for the quarter ended December 31, 2013 increased 113% to $123.6 million, from $58.0 million for the...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related